Motixafortide Is Effective in Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma Patients Treated with Quadruplet Therapy

Key Points

• Motixafortide significantly enhances hematopoietic progenitor cell mobilization in multiple myeloma.
• The study reports an increase in mobilization rates, achieving a notable efficacy outcome.
• Assessment through a clinical trial demonstrated improvements in cell mobilization with quadruplet therapy.
• This finding highlights potential benefits for treatment strategies in multiple myeloma patients.